Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Weisberg, Ellen
Item TypeName
Academic Article Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Academic Article Drug resistance in mutant FLT3-positive AML.
Academic Article Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.
Academic Article The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Academic Article Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Academic Article Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Academic Article Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Academic Article Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Academic Article Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Academic Article Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Academic Article Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
Academic Article An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRa and kit.
Academic Article Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Academic Article Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Concept Protein Kinase Inhibitors
Academic Article Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.
Academic Article Discovery of a selective irreversible BMX inhibitor for prostate cancer.
Academic Article Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
Academic Article Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Academic Article Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
Academic Article Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Academic Article Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances.
Academic Article Structure-guided development of covalent TAK1 inhibitors.
Academic Article Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies.
Academic Article Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Academic Article Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.
Academic Article Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
Academic Article Inhibition of USP10 induces degradation of oncogenic FLT3.
Academic Article A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.
Academic Article Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside".
Academic Article Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.